Tag: Ascletis Pharma Inc.

Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30

- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of...

Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment...

- The Phase I trial evaluates the safety, tolerability and preliminary efficacy of ASC50 for the treatment of psoriasis.- Preclinical data, including higher oral...

Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)

HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsAscletis Pharma Inc.

InventHelp Inventor Develops New Beverage Accessory (TLS-807)

BexBack Launches Limited-Time $50 Bonus, 100% Deposit Bonus Match, 100x Leverage, and No KYC Amid Bitcoin Surge Past $100K

Lifeway Foods Comments on Edward and Ludmila Smolyansky’s Consent Solicitation and Urges Shareholders to Disregard the Unlawful Consent Solicitation Statement

Tag: Ascletis Pharma Inc.

Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30

Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment...

Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us